6/30/2023 0 Comments Lucid motors ipoSuch forward-looking statements, which are based upon the current beliefs and expectations of Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Forward-looking statements are any statements that are not historical facts. This press release includes forward-looking statements. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. as a 510(k)-cleared esophageal cell collection device. Lucid’s EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Alternatively, copies of the final prospectus relating to the offering can be obtained, when available, from either of the following:Ĭantor Fitzgerald & Co., Attention: Capital Markets DepartmentĤ99 Park Avenue, 4th Floor, New York, NY Genuity LLC, Attention: Syndicate Departmentĩ9 High Street, Suite 1200, Boston, MA press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus and, when available, the final prospectus related to the offering can be accessed by visiting the SEC website at. The offering is being made only by means of a written prospectus. BTIG and Needham & Company are acting as co-lead managers for the offering.Ī registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission (“SEC”) on October 13, 2021. The offering is expected to close on or about October 18, 2021, subject to the satisfaction of customary closing conditions.Ĭantor and Canaccord Genuity are acting as joint book-running managers for the offering. Lucid’s common stock is expected to begin trading on The Nasdaq Stock Market under the ticker symbol “LUCD” on October 14, 2021. In addition, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions. The gross proceeds to Lucid from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Lucid, are expected to be $70,000,000. All of the shares are being offered by Lucid. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. NEW YORK–(BUSINESS WIRE)– $LUCD–Lucid Diagnostics Inc.
0 Comments
Leave a Reply. |